Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  American Journal of Human Genetics

• Publication date

  2001-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1086/324412PMID 11592034PMCID PMC1235559
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutant glycosyltransferase and altered glycosylation of α-dystroglycan in the myodystrophy mouse

  2001cited by this paper
• Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse.

  2001cited by this paper
• Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy.

  2001cited by this paper
• Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI

  2001cited by this paper
• Selective deficiency of α-dystroglycan in Fukuyama-type congenital muscular dystrophy

  2001influential reference
• Congenital muscular dystrophy associated with calf hypertrophy, microcephaly and severe mental retardation in three Italian families: evidence for a novel CMD syndrome.

  2000cited by this paper
• Biosynthesis of dystroglycan: processing of a precursor propeptide

  2000cited by this paper
• Congenital muscular dystrophy with secondary merosin deficiency and normal brain MRI: a novel entity?

  2000cited by this paper
• Neural Regulation of α‐Dystroglycan Biosynthesis and Glycosylation in Skeletal Muscle

  2000cited by this paper
• Assignment of a form of congenital muscular dystrophy with secondary merosin deficiency to chromosome 1q42.

  2000cited by this paper
• Merosin-deficient congenital muscular dystrophy with mental retardation and cerebellar cysts unlinked to the LAMA2, FCMD and MEB loci.

  2000cited by this paper
• Neural regulation of alpha-dystroglycan biosynthesis and glycosylation in skeletal muscle.

  2000cited by this paper
• Structure/function studies of glycosyltransferases.

  1999cited by this paper
• The fukutin protein family--predicted enzymes modifying cell-surface molecules.

  1999cited by this paper
• Dystroglycan inside and out.

  1999cited by this paper
• Assignment of the muscle-eye-brain disease gene to 1p32-p34 by linkage analysis and homozygosity mapping.

  1999cited by this paper
• α-Dystroglycan Is a Laminin Receptor Involved in Extracellular Matrix Assembly on Myotubes and Muscle Cell Viability

  1999cited by this paper
• Novel mutations and genotype-phenotype relationships in 107 families with Fukuyama-type congenital muscular dystrophy (FCMD).

  1999cited by this paper
• 68th ENMC international workshop (5th international workshop): On congenital muscular dystrophy, 9-11 April 1999, Naarden, The Netherlands.

  1999cited by this paper
• Mutations in the integrin α7 gene cause congenital myopathy

  1998cited by this paper
• An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy

  1998influential reference
• Tokyo campus rising

  1998cited by this paper
• Identification of a new locus for a peculiar form of congenital muscular dystrophy with early rigidity of the spine, on chromosome 1p35-36.

  1998cited by this paper
• An early onset muscular dystrophy with diaphragmatic involvement, early respiratory failure and secondary alpha2 laminin deficiency unlinked to the LAMA2 locus on 6q22.

  1998cited by this paper
• Localization of proteins to the Golgi apparatus

  1998cited by this paper
• Dystroglycan in development and disease.

  1998cited by this paper
• Mutations in the integrin alpha7 gene cause congenital myopathy.

  1998cited by this paper
• Electron microscopic examination of basal lamina in Fukuyama congenital muscular dystrophy.

  1997cited by this paper
• 50th ENMC International Workshop: congenital muscular dystrophy. 28 February 1997 to 2 March 1997, Naarden, The Netherlands.

  1997cited by this paper
• Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.

  1997cited by this paper
• Muscle—eye—brain disease: A neuropathological study

  1997influential reference
• Genetic epidemiology of congenital muscular dystrophy in a sample from north-east Italy

  1996cited by this paper
• Mutations in the laminin α2–chain gene (LAMA2) cause merosin–deficient congenital muscular dystrophy

  1995cited by this paper
• Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy.

  1995cited by this paper
• Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage.

  1995cited by this paper
• Phenotypic and Pathologic Evaluation of the myd Mouse. A Candidate Model for Facioscapulohumeral Dystrophy

  1995influential reference
• Proceedings of the 27th ENMC sponsored workshop on congenital muscular dystrophy. 22-24 April 1994, The Netherlands.

  1995cited by this paper
• Congenital muscular dystrophy with merosin deficiency.

  1994cited by this paper
• 22nd ENMC sponsored workshop on congenital muscular dystrophy held in Baarn, The Netherlands, 14-16 May 1993.

  1994cited by this paper
• Abnormal localization of laminin subunits in muscular dystrophies.

  1993cited by this paper
• Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix

  1992cited by this paper
• Membrane organization of the dystrophin-glycoprotein complex.

  1991cited by this paper
• Congenital progressive muscular dystrophy of the Fukuyama type - clinical, genetic and pathological considerations.

  1981cited by this paper
• Muscle disorders in childhood.

  1977cited by this paper

• A Novel LAMA2 Mutation (c.7412G>A) Was Found in a Chinese Patient With Congenital Muscular Dystrophy

  2025cites this paper
• Misregulation of the Ubiquitin–Proteasome System and Autophagy in Muscular Dystrophies Associated with the Dystrophin–Glycoprotein Complex

  2025cites this paper
• Segmental Strain and Strain‐Rate Imaging to Assess Cardiac Function in Patients With Limb‐Girdle Muscular Dystrophy R9: An Observational Study of the Norwegian LGMDR9 Cohort

  2025cites this paper
• Zebrafish as a Model Organism for Research in Rare Genetic Neuromuscular Diseases

  2025cites this paper
• Extracellular matrix: Dystroglycan interactions—Roles for the dystrophin‐associated glycoprotein complex in skeletal tissue dynamics

  2025cites this paper
• Ribitol and ribose treatments differentially affect metabolism of muscle tissue in FKRP mutant mice

  2025cites this paper
• Spatial Proteomics Reveals Distinct Protein Patterns in Cortical Migration Disorders Caused by LIN28A Overexpression and WNT Activation

  2025cites this paper
• Ribitol treatment rescues dystroglycanopathy mice with common L276I mutation

  2025cites this paper
• Molecular Study of the Fukutin-Related Protein (FKRP) Gene in Patients from Southern Italy with Duchenne/Becker-like Phenotype

  2024cites this paper
• Enhanced Diaphragm Muscle Function upon Satellite Cell Transplantation in Dystrophic Mice

  2024cites this paper
• Phenotype-genotype spectrum of a cohort of congenital muscular dystrophies: a single-centre experience from India

  2024cites this paper
• Break Down of the Complexity and Inconsistency Between Levels of Matriglycan and Disease Phenotype in FKRP-Related Dystroglycanopathies: A Review and Model of Interpretation

  2024cites this paper
• Exploring domain architectures of human glycosyltransferases: Highlighting the functional diversity of non-catalytic add-on domains.

  2024cites this paper
• Dual FKRP/FST gene therapy in a single AAV normalizes ambulation, increases muscle strength, decreases muscle pathology, and amplifies gene expression in the FKRPP448L model of LGMDR9.

  2024cites this paper
• Solute Carrier Family 35 (SLC35)—An Overview and Recent Progress

  2024cites this paper
• Efficacy and muscle safety assessment of fukutin-related protein gene therapy

  2023cites this paper
• CRISPR-Cas9 KO Cell Line Generation and Development of a Cell-Based Potency Assay for rAAV-FKRP Gene Therapy

  2023cites this paper
• Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I.

  2023cites this paper
• Clinical and genetic characteristics and an algorithm for the differential diagnosis of progressive muscular dystrophies that manifest after a period of normal motor development

  2023cites this paper
• Misfolding of fukutin-related protein (FKRP) variants in congenital and limb girdle muscular dystrophies

  2023cites this paper
• Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies

  2023cites this paper
• N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy

  2023cites this paper
• Mild limb girdle muscular dystrophy R9 phenotype caused by novel compound heterozygous FKRP gene mutation

  2023cites this paper
• Phenotype Genotype Characterization of FKRP-related Muscular Dystrophy among Indian Patients

  2023cites this paper
• An atypical expression of core α-Dystroglycan and Laminin-α2 in skin fibroblasts of patients with congenital muscular dystrophies

  2023cites this paper
• FKRP directed fibronectin glycosylation: A novel mechanism giving insights into muscular dystrophies?

  2022cites this paper
• Inherited myopathies in the Middle East and North Africa

  2022cites this paper
• Regulation of Dystroglycan Gene Expression in Early Myoblast Differentiation

  2022cites this paper
• Inhibitory CCK+ basket synapse defects in mouse models of dystroglycanopathy

  2022cites this paper
• The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction

  2022cites this paper
• Ribitol dose-dependently enhances matriglycan expression and improves muscle function with prolonged life span in limb girdle muscular dystrophy 2I mouse model

  2022cites this paper
• Post-translational Modification in Muscular Dystrophies.

  2022cites this paper
• Skeletal Muscle Cells Derived from Induced Pluripotent Stem Cells: A Platform for Limb Girdle Muscular Dystrophies

  2022cites this paper
• CDP-ribitol prodrug treatment ameliorates ISPD-deficient muscular dystrophy mouse model

  2022cites this paper
• Epidemiology and natural history in 101 subjects with FKRP-related limb-girdle muscular dystrophy R9. The Norwegian LGMDR9 cohort study (2020).

  2022cites this paper
• Protein O-mannosylation across kingdoms and related diseases: From glycobiology to glycopathology.

  2022cites this paper
• Dystroglycanopathy: From Elucidation of Molecular and Pathological Mechanisms to Development of Treatment Methods

  2021cites this paper
• FKRP-dependent glycosylation of fibronectin regulates muscle pathology in muscular dystrophy

  2021cites this paper
• Biosynthetic Mechanisms and Biological Significance of Glycerol Phosphate-Containing Glycan in Mammals

  2021cites this paper
• Muscular Dystrophies and Allied Disorders III

  2021cites this paper
• Congenital Disorders of Glycosylation

  2021cites this paper
• Defective autophagy and increased apoptosis contribute toward the pathogenesis of FKRP-associated muscular dystrophies

  2021cites this paper
• A Mosaic Mutation in the LAMA2 Gene in a Case of Merosin-deficient Congenital Muscular Dystrophy

  2021cites this paper
• FKRP mutations cause congenital muscular dystrophy 1C and limb-girdle muscular dystrophy 2I in Asian patients.

  2021cites this paper
• Inflammation, fibrosis and skeletal muscle regeneration in LGMDR9 are orchestrated by macrophages

  2021cites this paper
• Crystal structures of β-1,4-N-acetylglucosaminyltransferase 2: structural basis for inherited muscular dystrophies.

  2021cites this paper
• Revertant Phenomenon in DMD and LGMD2I and Its Therapeutic Implications: A Review of Study Under Mentorship of Terrence Partridge

  2021cites this paper
• The role of the Golgi apparatus in disease (Review)

  2021cites this paper
• NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes

  2021cites this paper
• A universal gene correction approach for FKRP-associated dystroglycanopathies to enable autologous cell therapy

  2021cites this paper
• Stereo- and Regioselective Synthesis of O-Mannosyl Glycan Containing Matriglycan and Part of the Tandem Ribitol Phosphate.

  2020cites this paper
• Congenital muscular dystrophy type 1A

  2020cites this paper
• Phenotypic Spectrum of α-Dystroglycanopathies Associated With the c.919T>a Variant in the FKRP Gene in Humans and Mice.

  2020cites this paper
• Cardiomyopathy in limb girdle muscular dystrophy R9, FKRP related

  2020influential citation
• Minimal Consequences of CMAH and DBA/2 Backgrounds on a FKRP Deficient Model

  2020cites this paper
• Efficient engraftment of pluripotent stem cell-derived myogenic progenitors in a novel immunodeficient mouse model of limb girdle muscular dystrophy 2I

  2020cites this paper
• Collagen VI-related limb-girdle syndrome caused by frequent mutation in COL6A3 gene with conflicting reports of pathogenicity.

  2020cites this paper
• Brain Dysfunction in LAMA2-Related Congenital Muscular Dystrophy: Lessons From Human Case Reports and Mouse Models

  2020cites this paper
• Crystal structures of fukutin-related protein (FKRP), a ribitol-phosphate transferase related to muscular dystrophy

  2020cites this paper
• The Roles of A-Dystroglycan in the Central Nervous System

  2020cites this paper
• Crystal structure of FKRP in complex with Ba ion, CDP-ribtol, and sugar acceptor

  2020cites this paper
• [Limb-Girdle Muscular Dystrophy type R9 linked to the FKRP gene: state of the art and therapeutic perspectives].

  2020cites this paper
• Limb Girdle Muscular Dystrophy and Therapy: Current progress in Cell and Gene-based approaches.

  2020cites this paper
• Novel Radiological Brain Anomalies in a Patient with Congenital Muscular Dystrophy due to FKRP Mexican Founder Mutation c.1387A > G: Review of the Literature

  2020cites this paper
• α-Dystroglycanopathy: Molecular Mechanism, Clinical Manifestations, and Therapeutic Approaches

  2020cites this paper
• Fukutin-Related Protein: From Pathology to Treatments.

  2020cites this paper
• Protein homeostasis in LGMDR9 (LGMD2I) – The role of ubiquitin–proteasome and autophagy–lysosomal system

  2020cites this paper
• Extracellular Control of Radial Glia Proliferation and Scaffolding During Cortical Development and Pathology

  2020cites this paper
• The Roles of A-Dystroglycan in the Central Nervous System

  2020cites this paper
• Clinical and genetic characteristics of congenital muscular dystrophies (part 2)

  2020cites this paper
• Human Mutation

  2019cites this paper
• Discovery of Novel Therapeutics for Muscular Dystrophies using Zebrafish Phenotypic Screens

  2019cites this paper
• Metabolomics Analysis of Skeletal Muscles from FKRP-Deficient Mice Indicates Improvement After Gene Replacement Therapy

  2019cites this paper
• Mammalian O-mannosyl glycans: Biochemistry and glycopathology

  2019cites this paper
• Metabolic and morphological disorientations in the liver and skeletal muscle of mice exposed to hexavalent chromium

  2019cites this paper
• Kobe University Repository : Kernel タイトル Tit le Ident ificat ion of a Post-t ranslat ional Modificat ion with Ribitol-Phosphate and Its Defect in Muscular Dystrophy 著者

  2019cites this paper
• Clinical and Molecular Diagnosis in Muscular Dystrophies

  2019cites this paper
• Current Approaches in Immunoassay Methods Focus on Skeletal Muscle Proteins

  2019cites this paper
• Therapeutic Monosaccharides: Looking back, moving forward.

  2019cites this paper
• Clinical Perspective of Posttranslational Modifications

  2019cites this paper
• Congenital muscular dystrophy a case study with a mutation in the POMT1 gene

  2019cites this paper
• Metabolic Toxicity and Alteration of Cellular Bioenergetics by Hexavalent Chromium

  2019cites this paper
• ISPD Overexpression Enhances Ribitol-Induced Glycosylation of α-Dystroglycan in Dystrophic FKRP Mutant Mice

  2019cites this paper
• Elimination of fukutin reveals cellular and molecular pathomechanisms in muscular dystrophy-associated heart failure

  2019cites this paper
• Clinical, genetic, and pathologic characterization of FKRP Mexican founder mutation c.1387A>G

  2019cites this paper
• A new patient‐derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α‐dystroglycan

  2019cites this paper
• Ocular Pathology of Fukuyama Congenital Muscular Dystrophy

  2018cites this paper
• Prevalence, pathological mechanisms, and genetic basis of limb‐girdle muscular dystrophies: A review

  2018cites this paper
• Distinct expression of functionally glycosylated alpha-dystroglycan in muscle and non-muscle tissues of FKRP mutant mice

  2018cites this paper
• The roles of dystroglycan in the nervous system: insights from animal models of muscular dystrophy

  2018cites this paper
• The molecular cross talk of the dystrophin–glycoprotein complex

  2018cites this paper
• Dose-Dependent Effects of FKRP Gene-Replacement Therapy on Functional Rescue and Longevity in Dystrophic Mice

  2018cites this paper
• Hereditary Myopathies

  2018cites this paper
• Update on muscle disease

  2018cites this paper
• Detection of variants in dystroglycanopathy-associated genes through the application of targeted whole-exome sequencing analysis to a large cohort of patients with unexplained limb-girdle muscle weakness

  2018influential citation
• Ribitol-phosphate—a newly identified posttranslational glycosylation unit in mammals: structure, modification enzymes and relationship to human diseases

  2018cites this paper
• Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice

  2018cites this paper
• Lissencephaly, Type II (Cobblestone Lissencephaly)

  2018cites this paper
• Histochemistry and Immunochemistry of Normal Muscle

  2018cites this paper
• Molecular Therapies for Muscular Dystrophies

  2018cites this paper